Transgenic mice expressing human HLA class II molecules provide a useful model for identifying HLA-restricted CD4 1 epitopes. However, the influence of endogenous murine H-2-restricted T cell responses on HLA-restricted responses is not known. In the present study, we show that HLA-DR1 transgenic mice deficient for H-2 class II expression (HLA-DR1 1/1 /IAb 0/0 ) exhibit an equivalent expression level of the transgene HLA-DR1 and a similar diversity in the TCR repertoire, but a slightly different number of CD4 1 peripheral T cells, when compared to HLA-DR1 transgenic mice in which H-2 class II molecules were retained (HLA-DR1
Introduction
The development of protective T cell immunity against infectious pathogens involves major histocompatibility complex (MHC) class I-restricted cytotoxic CD8 + Tcells (CTL) and MHC class II-restricted helper CD4 + Tcells. Antigen-specific CD8 + T cell immunity primarily involves direct elimination of antigenexpressing cells (1-3) while antigen-specific CD4 + T cells promote optimal CD8 + T cell (4, 5) and B cell activation (6) (7) (8) .
The T cell-mediated response to complex antigens involves recognition of selected peptide epitopes presented in the context of MHC molecules expressed on antigen-presenting cells (9) . The identification of immunogenic epitopes among the hundreds or thousands of potential epitopes present in an antigenic protein is thus a critical step in attempts to optimize T cell-mediated immunity, and is important for the development of efficient vaccines. However, the identification of specific epitopes from complex antigens can be a cumbersome and difficult process, due to the multiplicity of MHC molecules encoded by distinct gene loci in both mice and humans. Moreover, using T cell clones isolated from whole antigenstimulated cells it's not obvious to identify the specificity of the T cell epitopes and their restriction alleles. To address this problem, we and others have developed transgenic (Tg) mice expressing human leukocyte antigen (HLA) class I complexes to facilitate identification of immunogenic HLA class I-restricted CTL epitopes (10, 11) . This experimental animal model is also useful for in vivo studies of cellular immune responses to various candidate vaccines, and it represents an attractive vertebrate system with immunological relevance for the human immune system. However, currently available mice often fail to develop responses against CTL epitopes known to elicit HLA-class I restricted responses in humans. To increase the abundance of murine CD8 + T cells restricted by human HLA class I molecules, it is essential to eliminate endogenous expression of murine H-2 class I molecules in such a way that only the Tg HLA alleles act as restriction elements in the mice (12) (13) (14) . A number of novel CTL epitopes for various antigens have already been identified with these mice, and synthetic peptides representing these epitopes have been used to prepare therapeutic vaccines to treat cancer patients. But the therapeutic effects of these vaccines are still far from optimal. One of the reasons may lie in the absence of concomitant tumor-specific CD4 + T cell responses. Indeed, recent studies have underlined the importance of CD4 + helper T (T H ) lymphocytes in both the initiation and maintenance of CD8 + immune responses (15) (16) (17) (18) . Despite the accepted requirement for antigen-specific CD4 + T cells, only a limited number of helper T cell epitopes (T H epitopes) restricted by specific human alleles have been identified until now. We have therefore focused our efforts on developing an HLA-class II Tg animal model to facilitate identification of new immunogenic T H -epitopes. In the present study, we analyzed the HLA-DR1-restricted T cell responses elicited in HLA-DR1 Tg mice deficient for H-2 class II expression (HLA-DR1 +/+ /IAb 0/0 ), compared to those induced in 'classic' HLA-DR1 +/+ /IAb +/+ Tg mice. Our results demonstrate that there is competition for immunodominance between H-2 class II-and HLA class IIrestricted T cell responses, and suggest that the presence of endogenous H-2 class II molecules may introduce a bias in favor of H-2 class II-restricted over HLA-class II-restricted Tcell responses in HLA-DR1 +/+ /IAb +/+ mice. The data presented in this report are consistent with HLA-DR1 +/+ /IAb 0/0 mice, providing a more sensitive and specific model for identifying and characterizing HLA-DR1-restricted epitopes for a variety of human disease-associated Ags.
Methods

Mice
The mice used in this study were bred and maintained in pathogen free conditions in the animal facilities of the Pasteur Institute, Paris. The HLA-DR1 IAb 0/0 transgenic mice were obtained at the Pasteur Institute of Lille by back-crossing the original HLA-DR1 transgenic mice (19) 
Immunoscope analysis
The TCR repertoire of CD4 + T cells from naive transgenic mice was analysed for BV usage using oligonucleotides specific for each family of BV segments, as described elswhere (21) . In brief, spleen CD4 + T cells were positively selected on auto MACS (Miltenyi Biotec, Bergish Gladbach, Germany). RNA was prepared using the RNA easy Kit (Qiagen, Hilden, Germany) and reverse transcribed into cDNA using oligo (dT) and SuperScript II (Invitrogen, Carlsbad, CA). Half of the reaction product was then amplified by 40 cycles of PCR (annealing at 60°C) in 25 ll, in the presence of BV-specific primers and subjected to an elongation reaction (run-off) with internal BC or BJ fluorescent-tagged primers. The labeled products were then loaded on a 6% acrylamide/8 M urea gel and separated by a run of 7 h at 35 W on a 373 DNA sequencer (Applied Biosystems). Data were analyzed using immunoscope software (21) designed for this purpose.
Immunization with HBc and HBs antigen
The HBc antigen used in this study was produced in Escherichia coli and purchased at Diasorin (Baluggia, Italia). The recombinant preS2/HBs antigen (ayw HBV subtype) was derived from transfected mammalian cells (CHO) (22) . For HBc immunization (4 lg of HBc in 50 ll alum adjuvant; Serva, Heidelberg, Germany), mice were injected twice at the base of the tail. Similarly, for HBs immunization, 2 lg of HBs was injected and the mice were also immunized twice. Before immunization, all mice were anesthetized intraperitoneally (i.p.) with 75 mg/kg of pentobarbital (Ceva, Santé Animale, Libourne, France).
T cell proliferation assay
Twelve days after immunization, the spleen was removed from animals and placed in RPMI serum-free medium. Splenocytes were RBC-depleted and submitted to a Ficoll gradient, then cultured in RPMI supplemented with 10% FCS, 10 mM HEPES, 1 mM sodium pyruvate, 5 3 10 ÿ5 M 2-mercaptoethanol. The spleen suspension was then adjusted to 10 3 10 6 cells/ml (5 3 10 5 cells/well) and incubated with 20 lg/ml, 6 lg/ml or 2 lg/ml of peptide. The cell suspension was incubated in 3% FCS in complete medium for 72 h at 37°C in 5% CO 2 . One lCi of [ 
IL4 secretion assay
Twelve days after the last immunization with HBc Ag, the spleen suspension was stimulated with 20 lg/ml of HBc 111-125 or irrelevant HIV-1 Gag 263-277 peptide. After 4 h of incubation, IL4 secretion was determined by use of a cytokine secretion capture assay, following the protocol supplied by the manufacturer (Miltenyi Biotec, Bergish Gladbach, Germany) and adapted from Brosterhus et al. (23) . Cells were then labeled with IL4 catch antibody and PE-detection antibody and counterstained with FITC-labelled CD4 antibody. After additional labeling with anti-FITC microbeads, the CD4+ cells were sorted and analyzed by FACS for IL4 secretion. some differences were observed, they were not significant. Thus, all BV families and subfamilies are represented similarly in the three strains of mice. The CDR3 length distribution for each BV chain was also analyzed, using the RT-PCR-based immunoscope assay, as described in the Methods. Again, no significant differences between the three strains of mice were detected (Fig. 2B) .
Results
Expression
While numerous HLA class I-restricted CTL epitopes from various antigens are known, only a limited number of T H epitopes restricted by HLA-DR1 have been reported to date. In order to compare the two types of HLA-DR1-expressing mice, we thus took advantage of the fact that HLA-DR1-and H-2-IA-restricted epitopes have been identified for the hepatitis virus capsid (HBc) and envelope ( Simultaneously, an IFNc secretion assay was performed on these splenocytes, and no HBc 111-125 -HLA-DR1-restricted, IFNc-secreting CD4 + T cells were observed (data not shown). Thus, the CD4 + T cells that proliferated after stimulation with the HBc-derived peptide had the T H2 phenotype. + T H lymphocytes in both the initiation and maintenance of CD8 + immune responses. However, only a limited number of helper T H cell epitopes restricted by specific human alleles have been identified to date (25, 26) . HLA class II transgenic mice were first designed in order to study auto-immune disease (19, 27, 28) . More recently, HLA class II Tg animals that express HLA class II molecules in the absence of murine class II molecules (Ab 0/0 ) have been generated and were rapidly used for screening of epitopes for human vaccinology (29, 30) . In the present study, we evaluated the influence of endogenous H-2 class II restricted T cell responses on the HLA-DR1-restricted T cell responses in human HLA class II Tg mice. We therefore compared the HLA-DR1-restricted T cell responses in HLA-DR1 molecules and thus enhanced T cell thymic education in these mice. In addition, no significant difference in the CDR3 length distribution for each BV chain usage was observed between the three strains of mice, demonstrating that the transgenic complex HLA-DR1 is fully functional in the selection process, and suggesting that BV usage is determined mainly by intracellular processes (e.g. recombination events, promoter strength). We then examined and compared the antigen- Table 1 ). The same peptides elicited weak responses in half of the HLA-DR1 +/+ /IAb +/+ immunized mice; interestingly, all the mice exhibited strong H-2-restricted Tcell responses (Table  1 ). These findings indicate that coexpression of endogenous H-2 class II molecules interferes with the capacity of mice to respond efficiently to HLA-DR1-restricted antigenic peptides. The proliferative index (Fig. 3) correlated with the number of antigen-specific HLA-DR1-restricted T cells present in the immunized mice (Fig. 5) (32, 33) . In addition, as shown in vivo, peripheral competition between T lymphocyte populations each expressing monoclonally distinct TCR regulates the final size of these populations in lymphoid tissues (34) . This competition for immunodominance between HLA-DR1-and H-2 class IIeducated lymphocytes could provide a plausible explanation for the reduced size of the mobilized HLA-DR1 population in HLA-DR1 +/+ /IAb +/+ mice compared to HLA-DR1 +/+ /IAb 0/0 Tg mice. Given the abundance of peptide vaccine candidates, there is a growing need to evaluate their in vivo immunogenicity and their efficacy at inducing desired T-cell responses related to human diseases. For this purpose, the HLA-DR1 +/+ /IAb 0/0 Tg mice provide a more sensitive and specific screening model than the HLA-DR1 +/+ /IAb +/+ mice. The 'humanized' class II Tg mice thus represent a time-saving model for the identification and development of more promising vaccination strategies with relevance for human disease. 
